TriangleDISEASE & TREATMENT SETTING
refractory Multiple Myeloma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of Relapsed or Refractory Multiple Myeloma
Broader topic: Multiple Myeloma
- Source population
- Not part of this definition
- Disease extent
- refractory
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- prior therapy
- status
- stated
- derivation status
- source-attested
- derivation note
- Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
- source wording
- Treatment of Relapsed or Refractory Multiple Myeloma
Study evidence for this setting
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myelom
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Indication-specific source history
2019-07-03 · Xpovio (selinexor) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- fda-2c63f4a5e308bfee
- event date
- 2019-07-03
- event kind
- accelerated-approval
- drug or regimen
- Xpovio (selinexor)
- source indication text
- In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b8f6b6d586183413c7e2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-12-18 · Xpovio (selinexor) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- fda-a7a9faa75857a3a7
- event date
- 2020-12-18
- event kind
- traditional-approval
- drug or regimen
- Xpovio (selinexor)
- source indication text
- In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b8f6b6d586183413c7e2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-10-25 · Tecvayli (teclistamab-cqyv) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- fda-20487dac283432a9
- event date
- 2022-10-25
- event kind
- accelerated-approval
- drug or regimen
- Tecvayli (teclistamab-cqyv)
- source indication text
- Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-10d01c97e4f62e394410
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-08-09 · Talvey (talquetamab-tgvs) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- fda-77ce88783b2734fc
- event date
- 2023-08-09
- event kind
- accelerated-approval
- drug or regimen
- Talvey (talquetamab-tgvs)
- source indication text
- Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-07e77bdba4e281fb49f5
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-08-14 · Elrexfio (elranatamab-bcmm) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- fda-5ee1fc8706c9b847
- event date
- 2023-08-14
- event kind
- accelerated-approval
- drug or regimen
- Elrexfio (elranatamab-bcmm)
- source indication text
- Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-437c96fec1234e278012
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-07-02 · Lynozyfic (linvoseltamab-gcpt) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- fda-39ca2886a21209a6
- event date
- 2025-07-02
- event kind
- accelerated-approval
- drug or regimen
- Lynozyfic (linvoseltamab-gcpt)
- source indication text
- Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9d8f489e1fde5734a831
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-07-02 · linvoseltamab-gcpt · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- notice-290f2e6a70f2aa79
- event date
- 2025-07-02
- event kind
- approval-notification
- drug or regimen
- linvoseltamab-gcpt
- source indication text
- FDA approved linvoseltamab-gcpt, a bispecific B-cell maturation antigen -directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-20922be08c90e6ba
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-10-23 · belantamab mafodotin-blmf · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- notice-10e615a4fc4540e1
- event date
- 2025-10-23
- event kind
- approval-notification
- drug or regimen
- belantamab mafodotin-blmf
- source indication text
- FDA approved belantamab mafodotin-blmf, a B-cell maturation antigen -directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-29d861b96a3e37e4
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-05 · Tecvayli (teclistamab-cqyv) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- fda-06980eba1b1b89d2
- event date
- 2026-03-05
- event kind
- traditional-approval
- drug or regimen
- Tecvayli (teclistamab-cqyv)
- source indication text
- Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-10d01c97e4f62e394410
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-05 · teclistamab in combination with daratumumab hyaluronidase-fihj · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma-refractory-b00a2fc0
- event id
- notice-cb16804c23f46e0f
- event date
- 2026-03-05
- event kind
- approval-notification
- drug or regimen
- teclistamab in combination with daratumumab hyaluronidase-fihj
- source indication text
- FDA approved teclistamab in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
- match phrase
- refractory multiple myeloma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-b050e96dd06339f0
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice